Dunlop A. Sinclair 4
4 · Apellis Pharmaceuticals, Inc. · Filed Sep 19, 2025
Insider Transaction Report
Form 4
Dunlop A. Sinclair
Director
Transactions
- Sale
Common Stock
2025-09-19$22.95/sh−31,092$713,561→ 68,908 total(indirect: Indirect Owner (Epidarex)) - Other
Common Stock
2025-09-19−3,837→ 65,071 total(indirect: Indirect Owner (Epidarex))
Holdings
- 158,393
Common Stock
Footnotes (4)
- [F1]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP ("Epidarex") on June 20, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.73 to $23.27, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F3]The securities are held by Epidarex, and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
- [F4]Represents a stock distribution from Epidarex to a Limited Partner and General Partner of Epidarex, for no consideration.